Blog

Cell & Gene Therapies
Advances in cell and gene therapies: What does it mean for big pharma?
  • February 6, 2017
  • Valid Insight

Recent years have seen substantial progress in the search for cell and gene therapies, with new medicinal technologies presenting hope for tackling a wide range of diseases.1 Indeed, there are some experimental therapies currently in Phase II and Phase III that are hopeful for launch into the market within the next decade.2 There is tremendous opportunity […]

Formulary Lock Out
Formulary lock out in the US
  • January 29, 2017
  • Valid Insight

Patients in the US often hear the term ‘drug formulary’ when they go to see their physician. A formulary, essentially, is a list of prescription medicines that are readily available in the hospital or that are covered by the patient’s drug insurance plan. The contents of formularies provide a strong reflection of the business priorities […]

Understanding payer archetypes
  • January 24, 2017
  • Valid Insight

One-size-fits-all has become an outdated and non-recommendable approach in pharma business. During the period of blockbuster medical products, this approach was applicable – the wider drug developers cast their net, the greater the chances of expanding their market share. Another merit to this approach was that it made strategy development relatively less complex for pharma […]

Market Access
Valid News, Market Access Insights – Vol 01, Issue 01
  • January 17, 2017
  • Valid Insight

Valid News, Market Access Insights is our new newsletter. In Volume 01, Issue 01, we provide advice on how to weather pricing competition and prepare for reimbursement, as well as explain the role of confidential contracting for flexible pricing. The growing importance of patient-reported outcomes are also discussed. A global market access news round-up and […]

value added medicines
Challenges for the adoption of value added medicines
  • January 9, 2017
  • Valid Insight

Pharmaceutical and life science companies are confronted with increasing competition while working with limited resources, driving the need to improve their internal capability to innovate. Developing new innovative products, however, requires investments, commitment, time, and product potential. How can companies simultaneously work within budget and deliver innovation and value? This dilemma is fuelling the need […]

market access training
Training for market access teams
  • December 20, 2016
  • Valid Insight

With a growing number of companies bringing a host of new products into the healthcare market, payers are more determined than ever to scrutinise drug prices and reimbursement. Payer demands are increasingly dominating the business decision-making processes of pharmaceutical companies. Leaders in pharma are shifting their organisations away from a purely sales orientated approach towards […]

Taking a multipronged approach to commercialisation of assets
  • November 15, 2016
  • Valid Insight

Pharmaceutical companies invest in pipeline assets that are scientifically attractive. In reality, only a fraction of assets in development make it to market. The success rate of asset developmental candidates from 2006 to 2015 was reportedly only 9.6%.1 At every phase of asset development, there is a risk of failing to proceed to the next […]

Value-Based Pricing – the way forward?
  • November 8, 2016
  • Valid Insight

In an effort to contain costs and avoid the over-valuing of products, payer organisations in the pharmaceutical and life science industries have made price setting a standard practice. One solution that potentially prevents over-valuation of medicines is External Reference Pricing (ERP). However, with greater amounts of data due to research and technological developments, increased adoption […]

Pharma Market Access
Big data insights for market access: To trust or not to trust?
  • October 3, 2016
  • Valid Insight

Big data reportedly houses so much clinical and commercial insight that, once unlocked, it can increase our understanding of customers and markets, while also informing the design, development, and marketing of biopharmaceutical products and services. It can also drive positive health and economic outcomes. With tremendous volumes of data, companies have more resources (in the […]

PRO data
Curbing non-adherence with PRO data
  • September 23, 2016
  • Valid Insight

On average, it is estimated that over 50% of patients eventually abandon their treatment. Patient-reported outcomes (PROs) could facilitate efforts to reduce these figures. Defined as any data coming directly from patients about how they feel or function in relation to a health condition or its treatment – with no clinician interpretation to remove the […]